Aqtual Strengthens Executive Leadership with Appointment of Daniil Kalyuzhny as Chief Financial Officer to Support Next Phase of Growth
Aqtual, Inc., a precision medicine company pioneering active chromatin cell-free DNA (cfDNA) diagnostics, has announced the appointment of Daniil Kalyuzhny as its new Chief Financial Officer (CFO). The strategic leadership addition comes at a pivotal moment for the company as it advances its first therapy-selection diagnostic test toward clinical validation and commercialization while expanding the applications of its proprietary functional liquid biopsy platform through collaborations with biopharmaceutical companies, co-development initiatives, and strategic licensing partnerships.
The appointment reflects Aqtual’s continued commitment to strengthening its executive team as it transitions from platform development to commercial execution. With increasing momentum across its research and development programs, the company believes Kalyuzhny’s extensive experience in healthcare investment banking and financial strategy will help accelerate growth and maximize the value of its innovative diagnostic technologies.
Leadership Expansion Supports Strategic Growth
As Chief Financial Officer, Daniil Kalyuzhny will oversee Aqtual’s financial operations, long-term capital planning, fundraising initiatives, and strategic transaction activities. His responsibilities will include developing financial strategies that support the company’s expanding clinical programs, strengthening investor relationships, evaluating partnership opportunities, and guiding corporate development initiatives.
Working closely with Aqtual’s executive leadership team, Kalyuzhny will also play an important role in supporting the continued expansion of the company’s proprietary biobank, a valuable resource that underpins biomarker discovery, therapeutic research, and future data-driven collaborations with pharmaceutical and biotechnology partners.
The company views the appointment as an important step toward building the financial infrastructure necessary to support commercialization while maintaining the flexibility to pursue multiple strategic opportunities.
Advancing Precision Medicine Through Functional Liquid Biopsy
Aqtual is developing a new generation of precision medicine diagnostics based on active chromatin cell-free DNA, a novel approach designed to provide functional biological information that extends beyond traditional genetic mutation analysis.
Unlike conventional liquid biopsy technologies that primarily identify DNA mutations circulating in the bloodstream, Aqtual’s platform examines active chromatin patterns found within cell-free DNA. This allows researchers and clinicians to better understand gene activity and cellular behavior, potentially enabling more accurate therapy selection, treatment monitoring, and disease characterization.
The company believes this technology can provide physicians and pharmaceutical developers with more comprehensive biological insights, supporting personalized treatment decisions across multiple disease areas.
Its first therapy-selection assay is currently progressing toward clinical validation, representing a major milestone in the company’s commercial development strategy.
CEO Highlights Importance of Financial Leadership
Dr. Diana Abdueva, Founder and Chief Executive Officer of Aqtual, welcomed Kalyuzhny to the leadership team, emphasizing that the company’s expanding opportunities require experienced financial leadership capable of guiding strategic decision-making.
According to Abdueva, Aqtual has reached a stage where prioritizing investments, managing partnerships, and executing long-term business strategies have become increasingly important. She noted that Kalyuzhny brings valuable industry expertise, strong financial judgment, and extensive transaction experience that will help the company execute its ambitious growth plans while maintaining strategic focus.
His appointment reflects the company’s confidence in its technology platform and its readiness to pursue broader commercial opportunities.
Extensive Healthcare Investment Banking Experience
Before joining Aqtual, Daniil Kalyuzhny served as Managing Director within the Global Healthcare Group at BTIG, where he led investment banking coverage for companies operating in the diagnostics and life sciences tools sectors.
During his tenure, he advised executive management teams and boards of directors on a wide variety of strategic financial transactions, including mergers and acquisitions, capital raises, licensing agreements, and strategic partnerships.
Over the course of his investment banking career, Kalyuzhny participated in transactions totaling more than $25 billion, providing financial guidance to numerous companies developing innovative diagnostic technologies, precision medicine platforms, and life sciences research tools.
His experience spans every stage of corporate development, from emerging biotechnology startups to established healthcare organizations seeking strategic expansion opportunities.
This background provides Aqtual with valuable expertise as it continues to evaluate financing options, commercial partnerships, and future corporate growth initiatives.
Supporting Clinical Development and Commercialization
One of Kalyuzhny’s primary objectives will be ensuring that Aqtual has the financial resources necessary to successfully advance its lead clinical programs.
The company’s therapy-selection diagnostic is moving closer to commercialization, requiring continued investment in clinical validation studies, regulatory activities, manufacturing readiness, and commercial infrastructure.
At the same time, Aqtual continues expanding its platform technology through collaborations with pharmaceutical companies interested in utilizing functional liquid biopsy approaches for biomarker discovery and drug development.
Balancing these parallel growth initiatives requires disciplined capital allocation and careful financial planning.
Kalyuzhny’s expertise is expected to help the company prioritize investments while maximizing long-term shareholder value.
Expanding Partnership Opportunities
In addition to advancing its own diagnostic products, Aqtual is actively pursuing partnerships with pharmaceutical and biotechnology companies interested in incorporating its technology into drug development programs.
Its functional liquid biopsy platform has potential applications in several areas, including:
- Therapy selection
- Biomarker discovery
- Clinical trial patient stratification
- Drug response monitoring
- Companion diagnostic development
- Translational research
- Precision oncology programs
By collaborating with external partners, the company hopes to broaden the adoption of its platform while creating additional revenue opportunities through licensing agreements and co-development programs.
These collaborations also generate valuable biological data that further strengthen the company’s growing proprietary database.
Building a Proprietary Biobank
An important component of Aqtual’s long-term strategy is the continued expansion of its proprietary biobank.
This resource contains carefully collected biological samples linked with clinical outcomes, creating a rich foundation for biomarker discovery and validation.
As additional patient samples are incorporated, the company expects its database to become increasingly valuable for identifying novel disease signatures, validating new diagnostic approaches, and supporting pharmaceutical research programs.
The growing collection also positions Aqtual to pursue future data-driven partnerships with healthcare organizations, biotechnology companies, and pharmaceutical developers seeking access to high-quality molecular datasets.
A Focus on Long-Term Value Creation
Commenting on his appointment, Daniil Kalyuzhny said that one of the biggest challenges facing platform technology companies is determining how to effectively allocate resources across multiple promising opportunities.
He noted that Aqtual has established an impressive scientific foundation capable of supporting several long-term growth avenues. According to Kalyuzhny, the company now has an opportunity to build a financial strategy that aligns investment decisions with its broader vision of advancing precision medicine through innovative diagnostic technologies.
He expressed enthusiasm about joining the organization and contributing to its next stage of development.
Positioned for Continued Expansion
The appointment of a seasoned financial executive comes as Aqtual continues to mature into a commercially focused precision medicine company.
With its lead therapy-selection assay progressing toward clinical validation, expanding relationships within the biopharmaceutical industry, and an increasingly valuable proprietary biobank supporting biomarker research, the company is building multiple pathways for future growth.
Strengthening the executive leadership team with experienced financial expertise provides additional support as Aqtual prepares for commercialization, evaluates strategic partnerships, and explores new opportunities to extend the reach of its active chromatin cfDNA platform.
As precision medicine continues to reshape healthcare, Aqtual aims to position itself at the forefront of next-generation liquid biopsy innovation, combining advanced molecular science with strategic business execution to improve treatment selection and accelerate the development of personalized therapies.
About Aqtual, Inc.
Aqtual, Inc. is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual’s proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.